MedPath

Guangzhou HuiBoRui Biological Pharmaceutical Technology Co., Ltd

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment

Phase 1
Conditions
Corneal Neovascularization
Interventions
Drug: Placebo
First Posted Date
2020-11-06
Last Posted Date
2020-11-06
Lead Sponsor
Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd
Target Recruit Count
62
Registration Number
NCT04620109
Locations
🇺🇸

Parexel International, Glendale, California, United States

© Copyright 2025. All Rights Reserved by MedPath